T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical Trial Preparations, Signaling Major Shift to Clinical Stage with DKK40M Financing Secured

Contributed by: GlobeNewswire

Tags

Cancer

More Like This

BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development

BerGenBio Third Quarter Results 2024

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

BerGenBio Reports Third Quarter 2023 Financial Results

Sobi publishes Q3 2023 report: Strong revenue and solid performance

Immunovia Publishes Full Year Report for 2023

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options